Research Library

A library of peptide research, organized by hub.

Five subject hubs: peptide science fundamentals, analytical quality, evidence standards, compound profiles by pathway, and regulatory science. Every article separates molecule-level evidence from product-level status.

10 articles

Regulatory Science

Compounding regulation, intended-use doctrine, advisory committees, and editorial frameworks.

May 7, 2026·5 min

How to Write Responsible Scientific Product Content

Responsible scientific content explains identity, mechanism, evidence, limitations, and status without converting early research into a consumer promise.

Read article
May 6, 2026·5 min

Why Laboratory Research and Human Administration Must Stay Separate

A reagent can support a valid experiment without being suitable for administration. Human use requires a different evidence, quality, oversight, and consent framework.

Read article
May 5, 2026·5 min

What FDA's 2026 Compounding Advisory Agenda Signals for Several Research Peptides

An advisory-committee agenda signals active regulatory evaluation. It is neither an approval nor a final prohibition, and the outcome must be reported after the meeting.

Read article
May 4, 2026·5 min

The 503A Bulks List and Why Researchers Should Follow It

The 503A bulks process addresses whether certain substances may qualify for pharmacy compounding under defined conditions. It does not approve them as drugs.

Read article
May 3, 2026·5 min

Why Peptide-Related Impurities Receive Regulatory Attention

Peptide impurities may differ from the intended sequence by only one residue or modification while retaining biological or immune activity.

Read article
May 2, 2026·5 min

The Difference Between an Approved Active Ingredient and an Approved Product

A molecule can appear in an approved medicine while another product containing a similarly named ingredient remains unapproved, non-equivalent, or poorly characterized.

Read article
May 1, 2026·5 min

Why Compounded Drugs Are Not FDA-Approved Drugs

Compounding can serve legitimate patient needs under defined legal conditions, but compounded products do not undergo FDA premarket approval.

Read article
April 30, 2026·5 min

What FDA's Peptide Clinical Pharmacology Guidance Means for Researchers

FDA's peptide guidance shows how many variables must be understood before peptide evidence can support a development program.

Read article
April 29, 2026·5 min

How FDA Evaluates Intended Use for Online Research Products

FDA can infer intended use from the full commercial record, including what a company says, shows, bundles, links, and encourages customers to do.

Read article
April 28, 2026·5 min

Research Use Only Does Not Mean Regulation-Free

Research-use language is one fact in a broader regulatory analysis. Regulators evaluate the product, claims, audience, accessories, and commercial context together.

Read article